Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Human immunodeficiency virus hematology.

Paul A Volberding1, Kelty R Baker, Alexandra M Levine

  • 1University of California at San Francisco, San Francisco, CA 94121, USA.

Hematology. American Society of Hematology. Education Program
|November 25, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Light Chain Amyloidosis: Epidemiology, Staging, and Prognostication.

Methodist DeBakey cardiovascular journal·2022
Same author

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society-USA Panel.

JAMA·2020
Same author

National Academies Consensus Report on Functional Assessment for Adults With Disabilities.

Archives of physical medicine and rehabilitation·2019
Same author

Anemia and leukopenia following intravenous colloidal silver infusions-Clinical and hematological features, unique peripheral blood film appearance and effective therapy with supplemental oral copper and apheresis.

Clinical case reports·2019
Same author

Incidence of chemotherapy-induced peripheral neuropathy within 12 weeks of starting neurotoxic chemotherapy for multiple myeloma or lymphoma: a prospective, single-center, observational study.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2019
Same author

HIV Screening and Preexposure Prophylaxis Guidelines: Following the Evidence.

JAMA·2019
Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025
Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025
Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025
Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025
See all related articles

Potent antiretroviral therapy has changed human immunodeficiency virus (HIV) disease, leading to longer survival but also new hematologic complications and cancers. Hematology-oncology specialists need updated education to manage these evolving challenges in HIV care.

Area of Science:

  • Hematology-Oncology
  • Infectious Diseases
  • Virology

Background:

  • Potent antiretroviral therapy (ART) has significantly altered the natural history of human immunodeficiency virus (HIV) infection.
  • Longer survival due to ART has led to new or evolving complications, including malignancies and hematologic disorders.
  • ART itself can cause hematologic toxicities, impacting patient care.

Purpose of the Study:

  • To review the impact of ART on HIV-related hematologic complications and malignancies.
  • To discuss the evolving role of hematology-oncology specialists in comprehensive HIV care.
  • To summarize current understanding and management of HIV-associated hematologic disorders and cancers.

Main Methods:

  • Review of antiretroviral drug development and viral suppression strategies.

Related Experiment Videos

  • Analysis of HIV and ART effects on hematologic dyscrasias and clotting disorders.
  • Discussion of HIV-associated non-Hodgkin's lymphoma, Hodgkin's disease, and multicentric Castleman's disease, including recent clinical trials.

    • Main Results:

    • ART has decreased some traditional HIV complications but introduced new ones, necessitating hematology consultation.
    • Specific hematologic issues include dyscrasias, clotting disorders, and secondary infections like parvovirus.
    • HIV-associated lymphomas and multicentric Castleman's disease remain challenging, with ongoing research in chemotherapy and monoclonal antibody treatments.

    Conclusions:

    • The landscape of HIV care has shifted, requiring specialized hematology-oncology expertise.
    • Ongoing education is crucial for managing ART-related toxicities and HIV-associated malignancies.
    • Advances in understanding and treatment offer improved outcomes for complex hematologic conditions in HIV patients.